Supernus Pharmaceuticals Cash Flow from Investing Activities 2011-2024 | SUPN
Supernus Pharmaceuticals cash flow from investing activities from 2011 to 2024. Cash flow from investing activities can be defined as the total change in cash resulting from a companies investments
Supernus Pharmaceuticals Annual Cash Flow Investing
(Millions of US $) |
| 2023 |
$269 |
| 2022 |
$-217 |
| 2021 |
$-82 |
| 2020 |
$-35 |
| 2019 |
$-158 |
| 2018 |
$-413 |
| 2017 |
$-86 |
| 2016 |
$-36 |
| 2015 |
$-39 |
| 2014 |
$-3 |
| 2013 |
$-12 |
| 2012 |
$-49 |
| 2011 |
$34 |
| 2010 |
$26 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.592B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
